You just read:

Pharnext Announces the Opening of the First U.S. Study Site for its PLEO-CMT International Pivotal Phase 3 Trial in Charcot-Marie-Tooth Disease Type 1A

News provided by

Pharnext

25 Apr, 2016, 02:00 ET